Cumberland Pharmaceuticals Inc. (CPIX) EPS Estimated At $-0.08

July 14, 2018 - By Nadine Davis

Investors sentiment decreased to 0.69 in Q1 2018. Its down 0.17, from 0.86 in 2017Q4. It worsened, as 4 investors sold Cumberland Pharmaceuticals Inc. shares while 9 reduced holdings. 1 funds opened positions while 8 raised stakes. 4.09 million shares or 0.64% less from 4.12 million shares in 2017Q4 were reported.
Prudential Financial Inc holds 20,600 shares. 53,800 are owned by California Pub Employees Retirement System. Northern Corp has 0% invested in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) for 23,723 shares. Oakworth Incorporated has 0% invested in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) for 3,052 shares. Vanguard Group holds 313,764 shares or 0% of its portfolio. 3,316 are held by Sei Invests. Dimensional Fund Advsrs Limited Partnership has invested 0% in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Morgan Stanley holds 0% of its portfolio in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) for 20,415 shares. Bard Associates holds 83,215 shares or 0.28% of its portfolio. State Street holds 0% or 11,258 shares in its portfolio. Tower Rech Capital Ltd Limited Liability Company (Trc) owns 0% invested in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) for 431 shares. Ariel Limited Co invested in 1.01 million shares. United Financial Advisers Ltd Llc holds 16,626 shares or 0% of its portfolio. Deutsche Bancshares Ag reported 0% stake. Jw Asset Mgmt Limited Liability Corporation invested in 1.18% or 178,942 shares.

Since March 19, 2018, it had 2 insider buys, and 0 insider sales for $4,464 activity.

Analysts expect Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) to report $-0.08 EPS on August, 14.They anticipate $0.01 EPS change or 14.29 % from last quarter’s $-0.07 EPS. After having $-0.11 EPS previously, Cumberland Pharmaceuticals Inc.’s analysts see -27.27 % EPS growth. The stock increased 1.46% or $0.09 during the last trading session, reaching $6.24. About 1,133 shares traded. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has declined 14.79% since July 14, 2017 and is downtrending. It has underperformed by 27.36% the S&P500.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Ratings Coverage

Among 2 analysts covering Cumberland (NASDAQ:CPIX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cumberland had 2 analyst reports since April 17, 2018 according to SRatingsIntel. The company was initiated on Tuesday, April 17 by FBR Capital.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. The company has market cap of $98.04 million. It marketed products include Acetadote injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. It currently has negative earnings. The company's product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.